Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: May 3, 2013
Last updated: December 15, 2016
Last verified: December 2016
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: May 2017
  Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Seiwert T, Burtness B, Mehra R, Weiss J, Berger R, Eder J, Heath K, McClanahan T, Lunceford J, Gause C, Cheng J, Chow L. Pembrolizumab Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Safety, Clinical Activity, and Utility of PD-L1 Expression and Interferon-gamma Related Gene Expression as Predictive Biomarkers During a Non-randomized, Open-label Trial. Lancet Oncol. [e-pub 27May2016]. doi:
Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng J, Karantza V, Buisseret L. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol. 2016;[e-pub 2May2016]. doi: 10.1200/JCO.2015.64.8931